Neuron-specific Enolase and Chromogranin A as Markers of Neuroendocrine Tumours
Author Information
Author(s): E Baudin, A Gigliotti, M Ducreux, J Ropers, E Comoy, JC Sabourin, JM Bidart, AF Cailleux, R Bonaccini, P Ruffini, M Schlumberger
Primary Institution: Institut Gustave-Roussy
Hypothesis
This study aims to compare the sensitivity and specificity of neuron-specific enolase (NSE) and chromogranin A (CgA) in patients with neuroendocrine tumours (NET).
Conclusion
Chromogranin A is a more sensitive marker for neuroendocrine tumours than neuron-specific enolase.
Supporting Evidence
- Chromogranin A was elevated in 76 (59%) of the 128 NET patients.
- Neuron-specific enolase was elevated in 48 (38%) of the 128 NET patients.
- CgA had a higher sensitivity than NSE across all groups of NET patients.
- Elevated CgA levels were significantly associated with the presence of other secretions and heavy tumour burden.
- Raised NSE levels were significantly associated with poor tumour differentiation.
Takeaway
Doctors measured two substances in the blood to see how well they can help find and track certain tumors. One of them, called chromogranin A, is better at this than the other.
Methodology
Serum levels of NSE and CgA were measured in 128 patients with neuroendocrine tumours and 53 controls, and their sensitivity and specificity were compared.
Limitations
The study population had a high percentage of patients with extensive disease and previous treatments, which may affect the generalizability of the results.
Participant Demographics
128 patients (72 males, 56 females; mean age 53 ± 14 years; range 13-77 years).
Statistical Information
P-Value
0.0001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website